(ALDX) Aldeyra The - Ratings and Ratios

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a clinical-stage biotechnology company specializing in the development of innovative therapies for immune-mediated diseases. The companys lead product candidate, reproxalap, is a first-in-class reactive aldehyde species (RASP) modulator currently in Phase III clinical trials for the treatment of dry eye disease, a condition affecting millions worldwide. Aldeyras RASP modulation platform targets a novel pathway involved in inflammation and oxidative stress, offering potential therapeutic benefits across multiple immune-mediated conditions.

ADX-629, another orally administered RASP modulator, is under development for a range of indications, including COVID-19, atopic asthma, psoriasis, and alcohol intoxication. The compounds broad therapeutic potential underscores Aldeyras strategy to leverage its platform across diverse disease states. Additionally, ADX-2191, a dihydrofolate reductase (DHFR) inhibitor, is being investigated for the treatment of retinitis pigmentosa and other rare retinal diseases characterized by inflammation and vision loss. The company also has earlier-stage programs, including ADX-246 for systemic immune-mediated diseases and ADX-248 for geographic atrophy, further diversifying its pipeline.

Founded in 2004 and headquartered in Lexington, Massachusetts, Aldeyra Therapeutics operates with a focus on advancing its pipeline through clinical development and regulatory approval. The companys name change from Aldexa Therapeutics in 2014 reflects its strategic evolution and commitment to innovation in the biotechnology sector. With a market capitalization of approximately $398.39 million, Aldeyra is positioned as a mid-sized player in the biotech industry, with a pipeline that balances near-term opportunities with longer-term growth potential.